导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.07% | 1284/4773 |
| 近一周 | -2.41% | 2096/5462 |
| 近一月 | -3.84% | 2008/5421 |
| 近一季 | -5.46% | 1851/5209 |
| 近半年 | -4.84% | 2642/4920 |
| 近一年 | 7.46% | 1305/4366 |
| 近两年 | 56.70% | 1290/2954 |
| 近三年 | 28.84% | 1100/2253 |
| 成立以来 | 85.12% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.84% 1162/4961 |
14.44% 1814/5312 |
- - |
- - |
| 2025 | 22.89% 1929/4813 |
2.42% 1377/3635 |
1.04% 2487/4076 |
19.44% 2146/4524 |
-0.57% 2544/4813 |
| 2024 | 5.60% 1823/3463 |
-1.64% 1254/2808 |
-2.39% 1183/3014 |
11.32% 2530/3129 |
-1.20% 1625/3463 |
| 2023 | -5.39% 735/2656 |
5.84% 750/2280 |
-3.48% 805/2385 |
-3.04% 833/2515 |
-4.49% 1056/2655 |
| 2022 | -15.63% 424/2207 |
-12.55% 634/1919 |
4.81% 972/2016 |
-9.01% 236/2113 |
1.17% 1358/2208 |
| 2021 | 22.37% 147/1822 |
0.02% 322/1255 |
10.53% 457/1330 |
6.47% 223/1466 |
3.97% 378/1822 |
| 2020 | 24.10% 639/1250 |
-4.48% 369/1028 |
15.79% 474/1067 |
8.03% 742/1164 |
3.85% 886/1184 |
| 2019 | - - |
- - |
- - |
- - |
5.84% 670/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方上证380ETF联接C VS. 长安沪深300非周期A(740101) |